Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 ENTITLES HOLDERS TO RECEIVE NET PROCEEDS FROM SALE OF REMAINING LEGACY BIOSIMILAR ASSETS   COMPLETES TRANSFORMATION OF COHERUS ONCOLOGY INTO A FULLY INTEGRATED, INNOVATIVE IMMUNO-ONCOLOGY COMPANY  REDWOOD CITY, CALIF., AUG. 17, 2026 (GLOBE NEWSWIRE) -- COHERUS ONCOLOGY, INC.(NASDAQ: CHRS) (COHERUS, COHERUS ONCOLOGY OR THE COMPANY) TODAY ANNOUNCED A SPECIAL DIVIDEND OF CONTINGENT VALUE RIGHTS (EACH, A CVR AND COLLECTIVELY, THE CVRS), WHICH WILL BE DISTRIBUTED ON A PRO RATA BASIS TO STOCKHOLDERS OF RECORD OF THE COMPANY'S COMMON STOCK AS OF 5:00 P.M.

COHERUS ONCOLOGY ANNOUNCES SPECIAL DIVIDEND OF BIOSIMILAR CONTINGENT VALUE RIGHTS

 LOQTORZI NET REVENUE OF $13.6 MILLION IN Q2 2026, UP 15% OVER Q1   CLINICAL DATA CONTINUE TO MATURE ACROSS PROGRAMS WITH EMERGING EVIDENCE OF ACTIVITY WITH TAGMOKITUG IN HEAD AND NECK CANCER   PROJECTED OCTOBER PUBLIC DISCLOSURE OF DATA SETS WITH SUFFICIENT MATURITY   CONFERENCE CALL TODAY AT 5:00 P.M. EASTERN DAYLIGHT TIME  REDWOOD CITY, CALIF.

COHERUS ONCOLOGY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTSAND PROVIDES BUSINESS UPDATE

REDWOOD CITY, CALIF., JULY 22, 2026 (GLOBE NEWSWIRE) -- COHERUS ONCOLOGY, INC.(NASDAQ: CHRS), TODAY ANNOUNCED THAT ITS SECOND QUARTER 2026 FINANCIAL RESULTS WILL BE RELEASED ON WEDNESDAY, AUGUST 5, 2026. STARTING AT 5:00 P.M. EASTERN DAYLIGHT TIME ON AUGUST 5, 2026, COHERUS' MANAGEMENT TEAM WILL HOST A CONFERENCE CALL AND WEBCAST TO DISCUSS FINANCIAL RESULTS AND PROVIDE A GENERAL BUSINESS UPDATE.

COHERUS ONCOLOGY TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 5, 2026

 FIRST PATIENT DOSED IN A PHASE 1 STUDY EVALUATING ZM008, AN ANTI-LLT1 MAB, IN COMBINATION WITH LOQTORZI, A NEXT-GENERATION PD-1 INHIBITOR   FIRST PATIENT DOSED IN A PHASE 1 STUDY EVALUATING ZM008, AN ANTI-LLT1 MAB, IN COMBINATION WITH LOQTORZI, A NEXT-GENERATION PD-1 INHIBITOR 

COHERUS AND ZUMUTOR BIOLOGICS ANNOUNCE CLINICAL COLLABORATION TO EVALUATE ZM008 IN COMBINATION WITH LOQTORZI (TORIPALIMAB-TPZI)

 LOQTORZI NET REVENUE OF $11.8 MILLION IN Q1 2026   PATIENT ACCRUAL COMPLETE FOR 1L HCC PHASE 2 RANDOMIZED CLINICAL TRIAL FOR ANTI-IL27 CASDOZOKITUG, TIMING FOR DATA READOUTS TRACKING TO PROJECTIONS   TAGMOKITUG, CCR8 TREG DEPLETER DEVELOPMENT EXPANDS WITH PHARMACOLOGICAL AND CLINICAL PROGRAM DIFFERENTIATION, INCLUDING DOSE-RESPONSIVE IMMUNE EFFECTS, NO OFF-TARGET BINDING, ACCEPTABLE SAFETY   $167.0 MILLION IN QUARTER-END CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES   CONFERENCE CALL TODAY AT 5:00 P.M. EASTERN DAYLIGHT TIME  REDWOOD CITY, CALIF.

COHERUS ONCOLOGY REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

REDWOOD CITY, CALIF., MAY 04, 2026 (GLOBE NEWSWIRE) -- COHERUS ONCOLOGY, INC.(NASDAQ: CHRS), TODAY ANNOUNCED THAT ITS FIRST QUARTER 2026 FINANCIAL RESULTS WILL BE RELEASED AFTER MARKET CLOSE ON MONDAY, MAY 11, 2026. STARTING AT 5:00 P.M. EASTERN TIME ON MAY 11, 2026, COHERUS' MANAGEMENT TEAM WILL HOST A CONFERENCE CALL AND WEBCAST TO DISCUSS FINANCIAL RESULTS AND PROVIDE A GENERAL BUSINESS UPDATE.

COHERUS ONCOLOGY TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 11, 2026

 LOQTORZI NET REVENUE MORE THAN DOUBLED TO $40.8 MILLION IN 2025 FROM $19.1 MILLION IN 2024   REDUCED SECURED AND CONVERTIBLE DEBT BY 90% FROM $480 MILLION TO $38.8 MILLION OVER 2024-2025   $172.1 MILLION IN YEAR ENDING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES   CONFERENCE CALL TODAY AT 4:30 P.M. EASTERN STANDARD TIME  REDWOOD CITY, CALIF.

COHERUS ONCOLOGY REPORTS FULL YEAR AND FOURTH QUARTER 2025 FINANCIAL RESULTSAND PROVIDES BUSINESS UPDATE

REDWOOD CITY, CALIF., MARCH 02, 2026 (GLOBE NEWSWIRE) -- COHERUS ONCOLOGY, INC. (NASDAQ: CHRS), TODAY ANNOUNCED THAT ITS FULL YEAR AND FOURTH QUARTER 2025 FINANCIAL RESULTS WILL BE RELEASED AFTER MARKET CLOSE ON MONDAY, MARCH 9, 2026. STARTING AT 4:30 P.M. EASTERN TIME ON MARCH 9, 2026, COHERUS' MANAGEMENT TEAM WILL HOST A CONFERENCE CALL AND WEBCAST TO DISCUSS FINANCIAL RESULTS AND PROVIDE A GENERAL BUSINESS UPDATE.

COHERUS ONCOLOGY TO REPORT FULL YEAR AND FOURTH QUARTER 2025 FINANCIAL RESULTS ON MARCH 9, 2026

REDWOOD CITY, CALIF., FEB. 23, 2026 (GLOBE NEWSWIRE) -- COHERUS ONCOLOGY, INC. (NASDAQ: CHRS) TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL BE PRESENTING DURING UPCOMING CONFERENCES. THE PRESENTATIONS WILL BE ACCESSIBLE VIA WEBCAST THROUGH A LINK POSTED ON THE INVESTOR EVENTS CALENDAR SECTION OF THE COHERUS ONCOLOGY WEBSITE:HTTPS://INVESTORS.COHERUS.COM/EVENTS-PRESENTATIONS. A REPLAY OF THE PRESENTATION WILL BE AVAILABLE ON THIS SAME WEBSITE FOR APPROXIMATELY 90 DAYS.

COHERUS ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

THE OFFERING WAS LED BY HEALTHCARE-DEDICATED INVESTORS INCLUDING JANUS HENDERSON INVESTORS, HBM HEALTHCARE INVESTMENTS AND SAMSARA BIOCAPITAL

COHERUS ONCOLOGY, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK

REDWOOD CITY, CALIF., FEB. 12, 2026 (GLOBE NEWSWIRE) -- COHERUS ONCOLOGY, INC. (COHERUS OR THE COMPANY) (NASDAQ: CHRS), TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 28,600,000 SHARES OF THE COMPANY'S COMMON STOCK (THE OFFERING). THE SHARES OF COMMON STOCK ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $1.75 PER SHARE, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES IN THE OFFERING ARE BEING SOLD BY THE COMPANY. THE GROSS PROCEEDS TO COHERUS FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $50.1 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. THE COMPANY HAS GRANTED THE UNDERWRITERS OF THE OFFERING A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 4,290,000 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT FEBRUARY 17, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

Coherus BioSciences, Inc.

CHRS

Price

Financial Reports

No items found.

Press Releases

Coherus BioSciences, Inc.

CHRS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CHRS